Background Research has shown that 20–30% of prisoners meet the diagnostic criteria for attention-deficit hyperactivity disorder (ADHD). Methylphenidate reduces ADHD symptoms, but effects in prisoners are uncertain because of comorbid mental health and substance use disorders. Aims To estimate the efficacy of an osmotic-release oral system methylphenidate (OROS-methylphenidate) in reducing ADHD symptoms in young adult prisoners with ADHD. Method We conducted an 8-week parallel-arm, double-blind, randomised placebo-controlled trial of OROS-methylphenidate versus placebo in male prisoners (aged 16–25 years) meeting the DSM-5 criteria for ADHD. Primary outcome was ADHD symptoms at 8 weeks, using the investigator-rated Connors Adult ...
Abstract Background Attention-Deficit / Hyperactivity Disorder (ADHD) is prevalent at a higher rate ...
BACKGROUND: There is increasing recognition of attention-deficit/hyperactivity disorder (ADHD) in ad...
Introduction: Methylphenidate is the first-line pharmacological treatment of attention-deficit/hyper...
Background Research has shown that 20–30% of prisoners meet the diagnostic criteria for attention...
Background Research has shown that 20–30% of prisoners meet the diagnostic criteria for attention...
Background Attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent disorder, seen in 2...
Background It is estimated that 20–30% of prisoners meet diagnostic criteria for attention deficit h...
Background It is estimated that 20–30% of prisoners meet diagnostic criteria for attention deficit h...
Background It is estimated that 20–30% of prisoners meet diagnostic criteria for attention deficit h...
Background It is estimated that 20–30% of prisoners meet diagnostic criteria for attention deficit h...
Background: Attention deficit hyperactivity disorder (ADHD) is an inherited developmental disorder w...
Mis-diagnosis of attention deficit hyperactivity disorder (ADHD) is an important public health conce...
Purpose Effective diagnostic and treatment pathways for ADHD are needed in prison settings due to th...
Background Around 25% of prisoners meet diagnostic criteria for attention-deficit/hyperactivity dis...
Substance use disorders (SUD) and Attention deficit /hyperactivity disorder (ADHD) are persistent a...
Abstract Background Attention-Deficit / Hyperactivity Disorder (ADHD) is prevalent at a higher rate ...
BACKGROUND: There is increasing recognition of attention-deficit/hyperactivity disorder (ADHD) in ad...
Introduction: Methylphenidate is the first-line pharmacological treatment of attention-deficit/hyper...
Background Research has shown that 20–30% of prisoners meet the diagnostic criteria for attention...
Background Research has shown that 20–30% of prisoners meet the diagnostic criteria for attention...
Background Attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent disorder, seen in 2...
Background It is estimated that 20–30% of prisoners meet diagnostic criteria for attention deficit h...
Background It is estimated that 20–30% of prisoners meet diagnostic criteria for attention deficit h...
Background It is estimated that 20–30% of prisoners meet diagnostic criteria for attention deficit h...
Background It is estimated that 20–30% of prisoners meet diagnostic criteria for attention deficit h...
Background: Attention deficit hyperactivity disorder (ADHD) is an inherited developmental disorder w...
Mis-diagnosis of attention deficit hyperactivity disorder (ADHD) is an important public health conce...
Purpose Effective diagnostic and treatment pathways for ADHD are needed in prison settings due to th...
Background Around 25% of prisoners meet diagnostic criteria for attention-deficit/hyperactivity dis...
Substance use disorders (SUD) and Attention deficit /hyperactivity disorder (ADHD) are persistent a...
Abstract Background Attention-Deficit / Hyperactivity Disorder (ADHD) is prevalent at a higher rate ...
BACKGROUND: There is increasing recognition of attention-deficit/hyperactivity disorder (ADHD) in ad...
Introduction: Methylphenidate is the first-line pharmacological treatment of attention-deficit/hyper...